|  |  |  |
| --- | --- | --- |
| **The impact factors of** **Objective response** | **RECIST** | **GCIG** |
| **Univariate analysis** | **Univariate analysis** |
| **P-value** | **OR (95%CI)** | **P-value** | **OR (95%CI)** |
| Age | 0.240 |  | 0.840 |  |
| ECOG | 0.800 |  | 0.769 |  |
| Histology | 0.991 |  | >0.999 |  |
| FIGO stage | 0.336 |  | >0.999 |  |
| Neoadjuvant therapy | 0.729 |  | 0.200 |  |
| Residue tumor | 0.509 |  | 0.993 |  |
| Response status to platinum | 0.119 |  | 0.182 |  |
|  Resistant VS. Refractory | 0.075 | 3.657(0.878-15.242) | 0.326 | 3.600(0.280-46.359) |
|  Partially sensitive VS. Refractory  | 0.059 | 3.200(0.956-10.714) | 0.068 | 18.000(0.812-399.154) |
| Baseline CA125 | 0.576 |  | 0.030 |  |
|  200-500 VS. ≤200  | 0.671 | 0.792(0.269-2.327) | 0.028 | 0.050(0.003-0.719) |
|  ≥500 VS. ≤200  | 0.2999 | 0.452(0.101-2.024) | 0.016 | 0.025(0.001-0.504) |

Supplementary table 2. Predictive impact of factors on efficacy evaluated by the RECIST or the GCIG criteria. ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; RECIST, Response Evaluation Criteria in Solid Tumors version 1.1; GCIG, Gynecologic Cancer InterGroup.